MedPath

A Study on the Microcirculatory Characteristics of Meridian Phenomenon for the Heart and Lung Meridians Based on Patients With COPD

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Device: Laser doppler
Registration Number
NCT04045418
Lead Sponsor
Zhejiang Chinese Medical University
Brief Summary

Although some important progresses were made in the field of the meridian research, no breakthroughs have been achieved. Besides,there are some problems in meridian researches. Particularly, previous research of meridian phenomenon involved lots of subjective elements and outcomes.Researches that use modern scientific techniques to investigate the biological characteristics of meridian phenomenon are urgently needed. Therefore, this study is designed to assess the microcirculatory characteristics of meridian phenomenon for the Heart and Lung meridians by using laser doppler. Thus, the biological characteristics of meridian phenomenon could be presented objectively in a scientific methodology

Detailed Description

This study will include 40 patients diagnosed with chronic obstructive pulmonary disease (COPD) and 80 healthy volunteers. Laser doppler examination will be adopted to assess the microcirculatory characteristics of meridian phenomenon for Heart and Lung meridians in the physiology/pathological state. Moreover, the site specificity for the meridian-visceral association and surface-surface association between the Heart and Lung meridians will be investigated.Primary outcomes will be blood flow curve and blood perfusion units(PU).Furthermore, this study will build standardized techniques and schemes for detecting the microcirculatory characteristics of meridian phenomenon for Heart and Lung meridians. The results of this study could also provide scientific foundation for traditional meridian theories.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria

Inclusion criteria for the COPD group

  1. Patients should meet the above diagnostic criteria, and the severity of COPD is in the stage of GOLD 2 or 3 based on pulmonary function testing;
  2. COPD patients in the stable phase, who present with mild symptoms of cough, expectoration and short breath;
  3. 35 ≤ age ≤75 years, male or female;
  4. Patients have clear consciousness and could communicate with others normally;
  5. Patients could understand the full study protocol and have high adherence.Written informed consent is signed by themselves or their lineal kin.

Inclusion criteria for health volunteers

  1. Healthy volunteers who could provide a recent (in the past 3 month) medical examination report to confirm they have not any cardiovascular, respiratory, digestive, urinary, hematological, endocrine and neurological disease;
  2. age ≥20 years, male or female;
  3. Participants have clear consciousness and could communicate with others normally;
  4. Participants could understand the full study protocol and have high adherence .Written informed consent is signed by themselves or their lineal kin.
Exclusion Criteria

Exclusion criteria for the COPD group

  1. Patients who fail to meet the diagnostic criteria for COPD, or COPD patients in the phase of acute exacerbation;
  2. Patients have the following complications, which includes pneumonia, bronchial asthma, bronchiectasis, active tuberculosis, pneumothorax, chest trauma, tumors of the lung or thorax, and other confirmed respiratory diseases;
  3. Patients have concomitant conditions of heart diseases, such as chronic stable angina pectoris (CSAP);
  4. Patients have serious concomitant conditions and fail to treat them effectively, such as diseases of the digestive, urinary, respiratory, hematological, and nervous system;
  5. Patients have mental illness, severe depression, alcohol dependence or history of drug abuse;
  6. Pregnant or lactating patients; Patients are participating in other trials.

Exclusion criteria of health volunteers

  1. Participants have sudden severe diseases during the trial, such as cardiovascular diseases, liver diseases, kidney diseases, urinary diseases and hematological diseases.
  2. Participants have mental illness, severe depression, alcohol dependence or history of drug abuse;
  3. Pregnant or lactating participants ;
  4. Participants are participating in other trials.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
COPD groupLaser dopplerThis group will include 40 patients with chronic obstructive pulmonary disease (COPD).
Healthy intervention groupLaser dopplerThis group will include 40 healthy volunteers. Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. The washout period between the two sessions is at least one day.
Healthy control groupLaser dopplerThis group will include 40 healthy volunteers.
Primary Outcome Measures
NameTimeMethod
Blood flow curve5 minutes of baseline, 15 minutes during moxibustion and 5 minutes after stopping moxibustion.

The blood flow curve could reflect the microcirculatory flux in the measuring sites.

Blood perfusion units5 minutes of baseline, 15 minutes during moxibustion and 5 minutes after stopping moxibustion.

Perfusion units (PU)=concentration of moving blood cells (CMBC)×velocity (V)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

the Third affiliated hospital of Zhejiang Chinese Medical university

🇨🇳

Hanzhou, Zhejiang, China

the Third affiliated hospital of Zhejiang Chinese Medical university
🇨🇳Hanzhou, Zhejiang, China
Hantong Hu
Contact
86-18667103032
413351308@qq.com
Xiaoyu Li
Contact
86-15017541803
752616172@qq.com
© Copyright 2025. All Rights Reserved by MedPath